News

TipRanks on MSN18h

Genmab price target raised to $36 from $35 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Genmab (GMAB) to $36 from $35 and keeps a Buy rating on the shares following the Q2 report. The ...

Bolt Biotherapeutics, Inc.: Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Next-generation claudin 18.2 ISAC BDC-4182 now in Phase 1 dose-escalation study Cash balance of $48.5 million as of June 30, 2025 anticipated to fund key milestones through mid-2026 REDWOOD CITY, ...